• Explore /
  • Poster
  • / Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.

Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.

Abstract Poster

Authors

Julia Foldi

Julia Foldi

Yale School of Medicine, New Haven, CT

Julia Foldi , Adriana Kahn , Andrea Silber , Tao Qing , Emily Reisenbichler , Neal A. Fischbach , Justin Persico , Kerin B. Adelson , Anamika Katoch , Anees B. Chagpar , Tristen Park , Adam Blanchard , Kim Blenman , David L. Rimm , Lajos Pusztai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02489448

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 516)

DOI

10.1200/JCO.2022.40.16_suppl.516

Abstract #

516

Poster Bd #

288

Abstract Disclosures

Similar Posters

First Author: Shigehira Saji

First Author: Lajos Pusztai

First Author: Lajos Pusztai

First Author: Sibylle Loibl